Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization

Willis, 2000, The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies, Blood, 96, 808, 10.1182/blood.V96.3.808 Avet-Loiseau, 2002, Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation, Blood, 99, 2185, 10.1182/blood.V99.6.2185 Fonseca, 2003, Clinical and biologic implications of recurrent genomic aberrations in myeloma, Blood, 101, 4569, 10.1182/blood-2002-10-3017 Zojer, 2000, Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization, Blood, 95, 1925, 10.1182/blood.V95.6.1925 Drach, 1995, Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization, Cancer Res, 55, 3854 Zandecki, 1996, Multiple myeloma: almost all patients are cytogenetically abnormal, Br J Haematol, 94, 217, 10.1046/j.1365-2141.1996.d01-2939.x Nishida, 1997, The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization, Blood, 90, 526, 10.1182/blood.V90.2.526 Fonseca, 2003, The recurrent IGH translocations are highly associated with nonhyperdiploid variant multiple myeloma, Blood, 102, 2562, 10.1182/blood-2003-02-0493 Facon, 2001, Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy, Blood, 97, 1566, 10.1182/blood.V97.6.1566 Fonseca, 2002, Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an Eastern Cooperative Oncology Group study, Cancer Res, 62, 715 Konigsberg, 2000, Predictive role of interphase cytogenetics for survival of patients with multiple myeloma, J Clin Oncol, 18, 804, 10.1200/JCO.2000.18.4.804 Zojer, 2000, Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization, Blood, 95, 1925, 10.1182/blood.V95.6.1925 Barlogie, 1999, Total therapy with tandem transplants for newly diagnosed multiple myeloma, Blood, 93, 55, 10.1182/blood.V93.1.55 Drach, 1998, Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy, Blood, 92, 802, 10.1182/blood.V92.3.802 Avet-Loiseau, 1999, Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome, Blood, 94, 2583, 10.1182/blood.V94.8.2583.420a05_2583_2589 Elnenaei, 2003, Gene abnormalities in multiple myeloma: the relevance of TP53, MDM2, and CDKN2A, Haematologica, 88, 529 Smadja, 2001, Hypodiploidy is a major prognostic factor in multiple myeloma, Blood, 98, 2229, 10.1182/blood.V98.7.2229 Smadja, 2003, Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases, Genes Chromosomes Cancer, 38, 234, 10.1002/gcc.10275 van Lom, 1993, In situ hybridization on May-Grunwald Giemsa-stained bone marrow and blood smears of patients with hematologic disorders allows detection of cell-lineage-specific cytogenetic abnormalities, Blood, 82, 884, 10.1182/blood.V82.3.884.884 Bernell, 1996, Fluorescence in situ hybridization in combination with morphology detects minimal residual disease in remission and heralds relapse in acute leukaemia, Br J Haematol, 95, 666, 10.1046/j.1365-2141.1996.d01-1945.x Nickenig, 2001, New insights into the biology of multiple myeloma using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level, Ann Hematol, 80, 662, 10.1007/s002770100366 Hardan, 2004, Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis, Exp Hematol, 32, 254, 10.1016/j.exphem.2003.12.001 ISCN, 1995, An international system for human cytogenetic nomenclature Shimoni, 2002, Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the BioView (Duet) combined morphological and cytogenetical analysis, Leukemia, 16, 1413, 10.1038/sj.leu.2402581 Debes-Marun, 2003, Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma, Leukemia, 17, 427, 10.1038/sj.leu.2402797 Dascalescu, 1999, Interphase FISH: a rapid method for detecting malignant plasma cells in multiple myeloma patients submitted to autologous transplantation, Bone Marrow Transplant, 23, 687, 10.1038/sj.bmt.1701626 Dring, 2004, A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma, Clin Cancer Res, 10, 5692, 10.1158/1078-0432.CCR-04-0467 Tricot, 1997, Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants, J Clin Oncol, 15, 2659, 10.1200/JCO.1997.15.7.2659 Fassas, 2002, Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma, Br J Haematol, 118, 1041, 10.1046/j.1365-2141.2002.03757.x Zhu L, Somlo G, Zhou Bn, Shao J, Bedell V, Slovak ML, Liu X, Luo J, Yen Y. Fibroblast growth factor receptor 3 inhibited by short-hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther 2005. In press. Plowright, 2000, Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis, Blood, 95, 992, 10.1182/blood.V95.3.992.003k29_992_998 Chesi, 2001, Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma, Blood, 97, 729, 10.1182/blood.V97.3.729 Boersma-Vreugdenhil, 2003, Translocation of the IGH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH, Blood, 101, 1653, 10.1182/blood-2002-09-2968 Zojer, 2002, Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance, Br J Haematol, 117, 852, 10.1046/j.1365-2141.2002.03529.x Fiserova, 2002, Detection of 13q abnormalities in multiple myeloma using immunomagnetically selected plasma cells, Neoplasma, 49, 300 Fonseca, 2002, Genomic abnormalities in monoclonal gammopathy of undetermined significance, Blood, 100, 1417, 10.1182/blood.V100.4.1417.h81602001417_1417_1424 Nilsson, 2004, MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q), Genes Chromosomes Cancer, 41, 223, 10.1002/gcc.20078 Gertz, 1997, Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation, Bone Marrow Transplant, 19, 337, 10.1038/sj.bmt.1700670